Adagio Medical Holdings, Inc.

Adagio Medical Holdings, Inc. develops catheter-based medical devices for cardiac ablation, with a focus on treating ventricular tachycardia and other complex arrhythmias. The company sells its products directly to hospitals and medical centers, and also places consoles with customers to support catheter use. Its business is still in an early commercialization and clinical-development phase, so regulatory clearance, clinical evidence, and physician adoption are central to its progress. Adagio’s operating model combines product sales with ongoing R&D and clinical trial investment to support future product launches and broader market acceptance.

−100,0 %

2.44

2.24

— Adagio Medical Holdings, Inc.
%
Catheter products80% Disposable or consumable catheters sold for use with the company’s console platform in cardiac ablation procedures.
Console placement and lease-related revenue10% Console systems loaned or placed with customers, generating implied rental or lease revenue over time.
Clinical development and product advancement0% R&D and clinical trial activities that support regulatory approval and future commercialization rather than direct revenue.
Commercial support and physician education10% Sales, marketing, and clinical support used to build physician awareness and adoption of the platform.

Adagio sells primarily to hospitals and medical centers that perform electrophysiology and ablation procedures...

  • Hospitals and medical centersprimary

    Buy catheters and use the console platform for cardiac ablation procedures because they need clinically effective tools for treating arrhythmias.

  • Electrophysiologists and procedural physiciansprimary

    Influence adoption by choosing devices that are safe, effective, and easy to use in complex ablation cases.

  • Third-party payorsprimary

    Do not buy the product directly, but their coverage and reimbursement decisions determine whether hospitals can economically use the procedures.

  • International healthcare systemssecondary

    Country-level reimbursement and approval bodies affect whether products can be commercialized outside the U.S.

Adagio is headquartered in the United States and appears to generate revenue primarily from direct sales into U.S...

  • •United States is the core commercial and regulatory market
  • •Direct sales are made to U.S. hospitals and medical centers
  • •Non-U.S. markets require country-by-country reimbursement access
  • •Foreign currency exposure can affect reported revenue
  • •Global supply chain creates tariff and trade-policy sensitivity

Adagio’s strategy is centered on clinical innovation, regulatory progress, and physician adoption of its proprietary...

01
Complete and advance FULCRUM-VT clinical trial activitiesshort-term

Clinical evidence is essential to support regulatory progress, physician confidence, and future commercialization.

02
Optimize product design for safety and ease of usemedium-term

Better product performance can differentiate the platform in a competitive market and improve physician adoption.

03
Expand commercial reach and physician awarenessmedium-term

A larger sales and marketing footprint is needed to convert clinical interest into utilization and revenue.

04
Secure reimbursement and regulatory approvalsshort-term

Hospital adoption depends on coverage, reimbursement, and clearance to sell and use the products.

Adagio faces substantial execution risk because it is still dependent on regulatory approvals, clinical trial outcomes,...

high

Regulatory approval and clearance risk

The company must complete additional clinical testing and obtain clearances or approvals before broad U.S. commercialization.

Scope
Product launch timing and market access
Materiality
high
high

Clinical trial execution risk

FULCRUM-VT and other studies are central to proving safety and effectiveness, which affects adoption and regulatory progress.

Scope
Pipeline and commercialization
Materiality
high
high

Reimbursement and coverage risk

Hospitals rely on third-party payor coverage to justify use of the procedures, especially in complex arrhythmia care.

Scope
Demand conversion
Materiality
high
high

Competitive pressure from larger device companies

Competitors have greater resources for product development, pricing, physician marketing, and clinical publication activity.

Scope
Market share and utilization
Materiality
high
high

Going concern / financing risk

The company has limited revenue, recurring operating losses, and negative operating cash flow, increasing dependence on external capital.

Scope
Liquidity and continuity
Materiality
high
medium

Trade policy and tariff exposure

The company depends on a global supply chain and could face higher costs or disruption from tariffs and trade barriers.

Scope
Manufacturing and sourcing
Materiality
medium
Revenue recognition under ASC 606
Can shift quarterly revenue and comparability
Console loan and lease-related accounting
Affects gross margin and operating leverage
Research and development expense recognition
Creates high near-term operating losses during development phases
Business combination accounting
Reduces comparability across periods
Foreign currency effects
Adds volatility to reported revenue

Odyssey Health, Inc.

ODYY · Surgical & Medical Instruments & Apparatus

Catheter Precision, Inc.

VTAK · Surgical & Medical Instruments & Apparatus

Cadrenal Therapeutics, Inc.

CVKD · Pharmaceutical Preparations

Cardio Diagnostics Holdings, Inc.

CDIO · In Vitro & In Vivo Diagnostic Substances

AtriCure, Inc.

ATRC · Surgical & Medical Instruments & Apparatus

Medtronic plc

MDT · Electromedical & Electrotherapeutic Apparatus

: 11/08/2026